www.pharmaceuticalsky.

com

MICROBIAL LIMIT TEST

VALIDATION PROTOCOL
Protocol No.

Effective Date

Company Name and Address

Pharmasky Ltd.

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 2 of 12

TABLE OF CONTENTS

1.0 PRE APPROVAL …………………………………………………………. Page numbers

2.0 OBJECTIVE………………………………………………………………….

3.0 SCOPE………………………………………………………………………...

4.0 REFERENCE DOCUMENT………………………………………………...

5.0 RESPONSIBILITY…………………………………………………………...

6.0 VALIDATION METHOLOGY……………………………………………...

7.0 ACCEPTANCE CRITERIA …………………………………………………

8.0 REVALIDATION CRITERIA………………………………………………

9.0 RESULT REPORTING………………………………………………………

10 CONCLUSION………………………………………………………………...

11 KEY CONSIDERATIONS………………………………………………..

12 ABBERIVATIONS…………………………………………………………….

13 FLOW CHART ……………………………………………...

14 POST APPROVAL…………………………………………………………….

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 3 of 12

1.0 PRE APPROVAL SIGNATURES:

This document is prepared by the validation and the GMP compliance team of xxxxxxxxxxxxxxx
under the authority of Quality Control Authority. Hence this document before being effective
shall be approved by xxxxxxx QA & CQU team.

Prepared By:

……………………. …………………….. …………………….

(Name) (Signature) (Date)

Checked By

……………………. …………………….. …………………….

(Name) (Signature) (Date)

Approved by

……………………. …………………….. …………………….

(Name) (Signature) (Date)

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 4 of 12

2.0 OBJECTIVE:

To establish the documentary evidence that the method for Microbial limit test for Non-sterile
materials is capable of correctly estimating the microbial counts in the Materials. The validity of the
test results largely upon the adequacy of a Demonstration that the test specimens to which they
are applied do not, of them -selves, inhibit the multiplication, under the test condition, of
microorganisms that may be present.

The validation exercise shall demonstrate that the method employed is capable for correct
enumeration of microorganisms without adversely effecting the Growth even in case of materials,
which have antimicrobial activity.

3.0 SCOPE:

This validation protocol is applicable for validating the Microbial limit test of non-sterile products and
raw materials.

The protocol shall be used for validation of the methods applicable for all Dosage forms and
materials, which have requirement for Microbial limit test.

Whenever the method is used for Microbial limit test for scale up/ scale down Formulation, the
validation shall be done on only one strength of product.

4.0 REFERENCE DOCUMENT:

Following documents are referred during preparation of the protocol

Document Name Document Number

Microbial limit Test SOP

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 5 of 12

5.0 RESPONSIBILITY:
Trained Microbiologist or a suitable trained authorized person

6.0 VALIDATION METHODOLOGY

6.1 TOTAL VIABLE AEROBIC COUNT

% of Tween 20 in Buffered Sodium % Recovery of Microorganisms

chloride Peptone Solution

0.025 % Recovery not obtained

0.050% Recovery not obtained

0.075% Recovery less than 70%

0.1 % Recovery up to 70%

6.1.1 10 gm/ml of sample + 90 ml of Buffered Sodium Chloride Peptone + 0.1% Tween 20 / 80. (Solution
A) 1:10.
15 ml solution A + 60 ml of Buffered Sodium Chloride Peptone + 0.1 % Tween 20 1:50.
10 ml of solution A + 90 ml of Buffered Sodium chloride Peptone + 0.1% Tween 20 1:100.

6.1.2 Prepared six test tube containing 10 ml each from Solution A (1:10) and follow the same for the
other preparation i.e. Solution B (1:50) and Solution C (1:100) respectively.

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 6 of 12

6.1.3 Grow the bacterial cultures separately in Soyabean casein digest medium at 30°C to 350C for 24
hours and Fungal cultures separately in Soyabean casein digest medium at 20 0C to 250C for 48
hours. The organisms to be used are as mentioned
below.
- E.coli
- S. aures
- Salmonella
- Pseudomonas aeruginosa
- C. albicans
- A. niger
-Bile tolerant gram-negative bacteria (replaced the EP procedure "Test for
Enterobacteria and Certain Other Gram-Negative Bacteria")
6.1.4 Prepare reference suspension separately of the above organisms by diluting the broth cultures to
get containing about not less than 103 viable microorganisms per ml.

6.1.5 Add separately 1 ml of the culture dilutions of S. aureus, E. coli, Salmonella, Pseudomonas
aeruginosa, C. albicans, A. niger and other bacterial species prepared above in all the three sets
of six test tubes prepared from each solution A,B,C.

6.1.6 From each set pipette out 1 ml separately in two pre- sterilized Petri plate .Pour 20-22 ml of
liquefied Soyabean casein digest agar for the cultivation of bacteria and 20-22 ml of liquefied
Sabouraud dextrose agar for the cultivation of fungi.

6.1.7 Incubate plates of soyabean casein digest agar at 30 0C to 350C for 5 days and plates of Sabouraud
dextrose agar at 200C to 250C for 5 days.

6.1.8 Sample controls:

Inoculate 1.0 ml of solution A, B, and C in duplicate and add 20-22 ml soyabean casein digest agar
for bacterial count and Sabouraud dextrose agar for total combined mold and yeasts count
respectively. Incubate at 300C to 350C for bacterial count for 5 days and 200C to 250C for total
combined mold and yeasts count for 5 days.

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 7 of 12

6.1.9 Positive control

Inoculate1 ml of each of the diluted bacterial and fungal culture into two plates Each and add 20-
22 ml of soyabean casein digest agar and Sabouraud dextrose Agar respectively. Incubate at 30 0C
to 350C for bacterial culture for 5 days And at 200C to 250C for total combined mold and yeasts
count for 5 days.

6.1.10 Negative control for media:

Inoculate 1.0 ml of Buffered Sodium chloride Peptone Solution in four plates And add 20-22 ml
of soyabean casein digest agar into 2 plates and Sabouraud dextrose agar into other 2 plates
respectively. Incubate at 300C to 350C for bacterial culture for 5 days and at 200C to 250C for
total combined mold and yeasts count for 5 day.

6.2 TESTS FOR PATHOGENS:

6.2.1 Preparation of sample:

1.0 gm sample + 100 ml soyabean casein digest medium + 4% Tween 20

1.0 gm sample + 100 ml Fluid lactose medium + 4% Tween 20

100 ml Fluid lactose medium + 4% Tween 20 (Positive control)

100 ml soyabean casein digest medium + 4% Tween 20 ( Positive control)

6.2.2 Mix well to obtain uniform solution or suspension:

6.2.3 Grow the bacterial culture separately in soyabean casein digest medium at 300C to 350C for 24
hours. The organisms to be used are as mentioned below.

- E.coli
- S. aures
- Salmonella

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 8 of 12

- Pseudomonas aeruginosa

6.2.4 Prepare reference suspension separately of above organisms by diluting the The broth cultures
to get not less than 103 viable organisms per ml. Mix equal volume of each suspension.

6.25 Pipette 1.0 ml mix suspension of the microorganism separately in tube of Soyabean casein
digest medium and Fluid lactose medium containing the sample to be examined.

6.2.5 Incubate the tube of soyabean casein digest medium and Fluid lactose medium at 30 0C to 350C
for 24 to 48 hours and proceed for Isolation and Identification of Staphylococcus aureus,
Pseudomonas aeruginosa, Salmonella, Escherichia coli from this broth as per specified SOP.
7.0 ACCEPTANCE CRITERIA

7.1 Recovery of the test organisms should not be less than 70 % of the calculated value of the
inoculum suspension is to be obtained.

7.2 There shall not be failure in isolation and identification of organisms inoculated in the medium
along with material.

7.3 The negative control should show no growth.

8.0 REVALIDATION CRITERIA/ DEMONSTRATION OF METHOD SUITABILITY

Change in formulation where in new component has been added.

When concentration of preservative has been changed.

Major change in method for Microbial limit test like method for deactivation of Antimicrobial
activity.

Three batches of each product / materials shall be validated for Microbial limit Test.

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 9 of 12

The "absence of specified organisms" tests to provide procedures for demonstration of the
absence of Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella species & Escherichia
coli.

9.0 RESULT REPORTING / REVIEWING REQUIREMENTS

Report all results on a method validation report form. If results are unacceptable,
the method accordingly to rule out the affecting factor.

10.0 CONCLUSION …………………………………………………………………………………………………….

……………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………
……………

11.0 KEY CONSIDERATIONS:

Keeping in view regarding latest international harmonization rules some key considerations
should be discussed both by the working QA group and CQU.

1. The fundamental shortcomings of these tests in regards to the current good

manufacturing practice (CGMP) requirements for "absence of objectionable organisms"
should be discussed by scientific teams.

2. Product risk analysis including product use and route of administration, growth
potential, preservation, and other considerations which are recommended in
Pharmacopoeia texts must be properly taken into account. The quality group must take a
proper and reasonable scientific approach how to handle, validate and test in special
cases of product recalls due to presence of objectionable organisms.

3. Re-validation of existing tests to align with current harmonized standards and level of
detail should properly discussed and made by using a matrix approach.

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 10 of 12

4. A proper reporting format should be developed by both quality and documentation

teams.

5. Training microbiologists for the revised tests should be considered as a priority by both
validation and quality team during transfer of procedures.
12.0 ABBREVIATIONS

Abbreviations
QA Quality Assurance
SOP Standard Operative Procedure
GMP Good Manufacturing Practice
CQU Central Quality Unit

13.0 Flow charts

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 11 of 12

14.0 POST APPROVAL

Prepared by

……………………… ………………………. ………………………..

(Name) (Signature) (Date)

Prepared By Reviewed By Approved By

Signature

Date:
Designation:
 www.pharmaceuticalsky.com
Protocol No:
New/Supersedes:…………….. Date:………………
Reviewed on:
Effective Date:
MICROBIAL LIMIT TEST Review Due on:
VALIDATION PROTOCOL
Page No: 12 of 12

Checked by

……………………… ………………………. ………………………..

(Name) (Signature) (Date)

Approved by

……………………… ………………………. ………………………..

(Name) (Signature) (Date)

Prepared By Reviewed By Approved By

Signature

Date:
Designation: